HOOKIPA Pharma Past Earnings Performance
Past criteria checks 0/6
HOOKIPA Pharma's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 7.6% per year.
Key information
-21.4%
Earnings growth rate
60.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 7.6% |
Return on equity | -90.8% |
Net Margin | -405.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts
May 18Hookipa: Speculative Biotech With Key Catalysts In 2022
Mar 29Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Oct 01Checking Back In On HOOKIPA Pharma
Jun 22Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers
Jun 08Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Apr 19If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns
Mar 15What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?
Jan 22Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside
Dec 31Introducing HOOKIPA Pharma (NASDAQ:HOOK), A Stock That Climbed 55% In The Last Year
Dec 11HOOKIPA Pharma prices public offering of common stock and preferred stock
Dec 09Revenue & Expenses BreakdownBeta
How HOOKIPA Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 20 | -82 | 20 | 0 |
30 Sep 23 | 21 | -69 | 20 | 0 |
30 Jun 23 | 16 | -68 | 20 | 0 |
31 Mar 23 | 16 | -67 | 20 | 0 |
31 Dec 22 | 14 | -65 | 20 | 0 |
30 Sep 22 | 10 | -74 | 20 | 0 |
30 Jun 22 | 12 | -76 | 20 | 0 |
31 Mar 22 | 15 | -76 | 20 | 0 |
31 Dec 21 | 18 | -76 | 19 | 0 |
30 Sep 21 | 20 | -67 | 21 | 0 |
30 Jun 21 | 20 | -60 | 21 | 0 |
31 Mar 21 | 21 | -50 | 20 | 0 |
31 Dec 20 | 20 | -44 | 20 | 0 |
30 Sep 20 | 18 | -42 | 19 | 0 |
30 Jun 20 | 16 | -40 | 19 | 0 |
31 Mar 20 | 13 | -45 | 19 | 0 |
31 Dec 19 | 12 | -43 | 17 | 0 |
30 Sep 19 | 13 | -35 | 14 | 0 |
30 Jun 19 | 13 | -27 | 10 | 0 |
31 Mar 19 | 10 | -21 | 8 | 0 |
31 Dec 18 | 8 | -16 | 7 | 0 |
Quality Earnings: HOOK is currently unprofitable.
Growing Profit Margin: HOOK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HOOK is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare HOOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HOOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: HOOK has a negative Return on Equity (-90.79%), as it is currently unprofitable.